At a glance

What it is

What KPV is

KPV is a short chain of three amino acids: lysine (K), proline (P) and valine (V). Those three are the final stretch of alpha-melanocyte-stimulating hormone, called alpha-MSH. Alpha-MSH is a larger hormone your body makes. It helps dial down inflammation and also affects skin pigment.

KPV is only a fragment. In lab work it keeps some of the anti-inflammatory activity of the full hormone and does not appear to carry the pigment effect. That is a laboratory finding, not something shown in patients.

KPV is not a hormone replacement and it is not a vitamin. It is an experimental peptide that has never been through the human trials needed for FDA approval. Online sellers describe it as a general inflammation and healing aid. Those descriptions go well beyond what the research supports.

How it is thought to work

How KPV is thought to work

In cell and animal studies, KPV appears to quiet an inflammatory switch called NF-kappaB and to reduce inflammatory signals such as interleukin-1 beta. Researchers have also proposed that a gut transporter called PepT1 carries KPV into intestinal cells, where it may calm inflammation. These are proposed mechanisms from the lab.

How much KPV reaches the body is also unclear. FDA staff found no studies of how it is absorbed or cleared in any species. One test on human skin from a cadaver found that KPV passes poorly through skin. That may limit how much reaches the blood from a cream, and it may also limit how useful a cream could be.

Evidence

What the studies show

The research is mostly in mice, rats and cultured cells. In mouse models of inflammatory bowel disease, KPV given by mouth or by injection reduced signs of colitis, and later work packaged KPV in nanoparticles to deliver it to the colon in mice. A rat colitis study used a hydrogel to hold the peptide. Rodent wound-healing studies were also reported. Findings in rodents often do not carry over to people.

FDA staff searched the medical literature and did not find a study in which KPV, compounded or not, was given to people. In their July 2026 briefing, they said there is a lack of evidence to judge whether it works and a lack of clinical and nonclinical safety information. They also found no studies of its effect on pregnancy or reproduction and none on cancer risk.

Plainly put: there is no human trial showing that KPV treats colitis, heals wounds or reduces inflammation in a person. Anyone who tells you otherwise is describing a hope. Individual results vary, and animal results cannot be read as human results.

If your goal is a gut condition such as ulcerative colitis or Crohn disease, approved treatments with human trial evidence exist, and a gastroenterologist guides them. KPV would not replace them.

Safety

Safety unknowns

The main safety fact is what is missing. No human safety data from trials exist. Side effects, long-term effects, and interactions with other medicines have not been studied in people, so no one can give you a reliable list of what to expect.

FDA staff also raised product-quality concerns that apply to any peptide made this way. Peptides can clump together, and clumps can trigger immune reactions. Peptide purity, contamination during manufacture and the stability of a cream, gel or injection are all open questions for KPV. The nomination that first brought KPV to FDA was withdrawn, and the nominator’s paperwork was inconsistent about which form of KPV was meant.

Who should not use it

Who should not use KPV

Because there are no human data, the list of people who should avoid it is long. Dr. Miranda is likely to advise against it for:

• Anyone who is pregnant, trying to become pregnant or breastfeeding, since no reproductive studies exist
• Children and teenagers
• People with a current or past cancer, including melanoma, since cancer-risk studies are missing
• People with an active infection or a weakened immune system, or who take immune-suppressing drugs, since KPV acts on inflammation pathways
• Anyone with an unexplained skin lesion or non-healing wound, which needs an examination first rather than a peptide
• People with inflammatory bowel disease who would use it in place of treatment from their gastroenterologist
• Anyone with an allergy to peptides or to ingredients in the compounded product

This is not a complete list. Tell the physician about every medicine, supplement and condition before any decision.

Sports

KPV and drug testing

The World Anti-Doping Agency’s 2026 Prohibited List has a catch-all category, S0, for any pharmacological substance with no current approval by a government regulatory health authority for human therapeutic use. It is prohibited at all times, in and out of competition. KPV has no such approval anywhere that we could find. We did not find KPV named on the list, but it appears to fall under S0. If you are subject to drug testing, check with your sport’s governing body or anti-doping agency before using it.

Regulatory status

KPV and pharmacies: the timeline

April 2026. KPV was removed from the FDA’s Category 2 list of substances that raise significant safety concerns, after the nomination was withdrawn. That did not make it compoundable.

July 23-24, 2026. FDA’s Pharmacy Compounding Advisory Committee reviewed KPV for use in wound healing and inflammatory conditions. Law-firm summaries report that the committee voted 8 to 6, with 1 abstention, to recommend adding KPV to the 503A bulks list. FDA review staff had proposed adding none of the substances. A committee vote is advice only. It does not change the law.

October 28, 2026. Enforcement discretion was granted allowing 503A compounding pharmacies to compound six peptide bulk substances: BPC-157, epitalon, KPV, MOTS-c, semax and TB-500. The National Community Pharmacists Association reported it on October 29, 2026, and described it as an FDA action. The Federal Register notice shows it is a policy of the Secretary of the Department of Health and Human Services (HHS), called the "Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances." The notice was filed on October 28 and published on October 30, 2026. It does not say how long the policy will last.

What the policy says. HHS states that it does not intend to take enforcement action against a state-licensed pharmacy, federal facility or licensed physician compounding with one of the six listed peptides, while the 503A bulks list is developed through rulemaking. HHS calls the policy a draft, interim policy, took public comments through about November 13, 2026, and says it may revisit the policy if a safety signal or product quality issue arises. The policy confers no legal rights on anyone.

Conditions. The policy sets ten conditions a pharmacy must meet. In plain words, they include: the peptide matches the listed identity and route for that peptide, with KPV limited to the acetate form, topical and oral only; the raw substance comes from an FDA-registered facility with a certificate of analysis; the original manufacturer follows good manufacturing practice; the product has only one active ingredient; oral products need documentation of adequate absorption in humans; the label says it is compounded and not for resale; serious side effects and quality problems are reported to FDA’s MedWatch; and every other compounding rule still applies, including a valid prescription for an individual patient.

Still pending. Formal rulemaking to add these substances to the 503A bulks list has not been completed. Enforcement discretion is not approval, and it is not the same as being on the list. FDA’s future rulemaking may or may not add KPV.

In plain terms, licensed 503A pharmacies can currently prepare KPV for an individual patient under a prescription without federal enforcement action. KPV is not an FDA-approved drug. The compounded product is not evaluated by FDA for safety, effectiveness or quality. This status can change as rulemaking proceeds, and the page date is November 10, 2026.

Summit’s role

What Summit does with KPV

Dr. Miranda decides whether KPV fits you after your history and labs. Nothing on this page promises a prescription, and given how little is known, many people will be told it is not a good fit.

If he does prescribe it, a state-licensed pharmacy prepares it for you as a named patient. Summit does not dispense or sell it and keeps no stock. The visit covers what is known, what is not, and how you and he will judge whether to continue.

See pricing for what the program includes, including labs.

Keep reading

Related medications

Sources

Where this comes from

All retrieved November 10, 2026.

1. HHS. Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, with Appendix A and B. Federal Register FR Doc 2026-22192, October 30, 2026. https://www.hhs.gov/sites/default/files/hhs-503a-peptide-enforcement-discretion-policy-appendix-b.pdf
2. FDA. July 23-24, 2026 Pharmacy Compounding Advisory Committee meeting page, including the uses evaluated for KPV. https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026
3. FDA. Briefing document for KPV-related bulk drug substances, July 2026. https://www.fda.gov/media/193346/download
4. HHS. Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances. Federal Register notice of availability, Vol. 91, No. 209, October 30, 2026 (FR Doc. 2026-22192). https://www.govinfo.gov/content/pkg/FR-2026-10-30/html/2026-22192.htm
5. NCPA. FDA grants enforcement discretion to compounding six peptides. October 29, 2026. https://ncpa.org/newsroom/qam/2026/10/29/fda-grants-enforcement-discretion-compounding-six-peptides
6. Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease. Inflamm Bowel Dis 2008. https://pubmed.ncbi.nlm.nih.gov/18092346/
7. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology 2008. https://pubmed.ncbi.nlm.nih.gov/18061177/
8. Orally targeted delivery of tripeptide KPV via hyaluronic acid-functionalized nanoparticles alleviates ulcerative colitis in mice. Mol Ther 2017. https://pubmed.ncbi.nlm.nih.gov/28143741/
9. Alpha-melanocyte-stimulating hormone and related tripeptides: biochemistry, antiinflammatory and protective effects in vitro and in vivo. Endocr Rev 2008. https://pubmed.ncbi.nlm.nih.gov/18612139/
10. World Anti-Doping Agency. Prohibited List 2026, section S0 non-approved substances. https://www.wada-ama.org/en/prohibited-list